Vivos Therapeutics (NASDAQ:VVOS) Trading 9.9% Higher – What’s Next?

Vivos Therapeutics, Inc. (NASDAQ:VVOS)’s share price was up 9.9% on Tuesday . The stock traded as high as $0.54 and last traded at $0.4622. 33,641,816 shares were traded during mid-day trading, an increase of 22,065% from the average daily volume of 151,780 shares. The stock had previously closed at $0.4206.

Analysts Set New Price Targets

VVOS has been the subject of several analyst reports. HC Wainwright reduced their target price on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a report on Friday, April 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Finally, Ascendiant Capital Markets upped their target price on shares of Vivos Therapeutics from $3.00 to $3.10 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Vivos Therapeutics has a consensus rating of “Hold” and a consensus price target of $2.80.

Vivos Therapeutics Price Performance

The company’s 50-day moving average price is $0.50 and its 200-day moving average price is $0.98. The company has a market cap of $4.47 million, a P/E ratio of -0.15 and a beta of 6.22.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%.The firm had revenue of $5.14 million for the quarter, compared to analyst estimates of $4.35 million. On average, equities research analysts predict that Vivos Therapeutics, Inc. will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Vivos Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC bought a new position in shares of Vivos Therapeutics during the first quarter worth approximately $28,000. Acorn Wealth Advisors LLC acquired a new position in Vivos Therapeutics in the 4th quarter worth about $30,000. XTX Topco Ltd acquired a new position in Vivos Therapeutics in the 2nd quarter valued at approximately $65,000. B. Riley Wealth Advisors Inc. bought a new position in shares of Vivos Therapeutics during the second quarter worth about $220,000. Finally, DRW Securities LLC grew its holdings in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after acquiring an additional 74,441 shares during the period. Institutional investors and hedge funds own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.